Literature DB >> 8397302

Results of antiemetic management in terminal illness.

I Lichter1.   

Abstract

A wide variety of causes may be responsible for nausea and vomiting in terminal illness. The different emetic stimuli reach the vomiting centre by a variety of pathways and can be blocked by specific antiemetics that act at the neurotransmitter receptor sites in these pathways. A knowledge of the neurotransmitter receptor antagonist potency of the different antiemetics allows the choice of the most appropriate antiemetic for the relief of the nausea and vomiting caused by a particular emetic stimulus. To demonstrate the efficacy of this approach to the management of nausea and vomiting in terminal illness, the outcome of antiemetic choice in 100 consecutive episodes is recorded.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8397302

Source DB:  PubMed          Journal:  J Palliat Care        ISSN: 0825-8597            Impact factor:   2.250


  11 in total

1.  An open study of methotrimeprazine in the management of nausea and vomiting in patients with advanced cancer.

Authors:  A Kennett; J Hardy; S Shah; R A'Hern
Journal:  Support Care Cancer       Date:  2005-02-08       Impact factor: 3.603

2.  An assessment of aetiology-based guidelines for the management of nausea and vomiting in patients with advanced cancer.

Authors:  Jeffrey Stephenson; Andrew Davies
Journal:  Support Care Cancer       Date:  2005-10-15       Impact factor: 3.603

Review 3.  Systematic review of the efficacy of antiemetics in the treatment of nausea in patients with far-advanced cancer.

Authors:  Paul Glare; Glenn Pereira; Linda J Kristjanson; Martin Stockler; Martin Tattersall
Journal:  Support Care Cancer       Date:  2004-04-24       Impact factor: 3.603

Review 4.  Role of supportive care for terminal stage hepatocellular carcinoma.

Authors:  Manoj Kumar; Dipanjan Panda
Journal:  J Clin Exp Hepatol       Date:  2014-03-31

Review 5.  [Treatment of nausea and vomiting with prokinetics and neuroleptics in palliative care patients : a review].

Authors:  G Benze; B Alt-Epping; A Geyer; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

Review 6.  Treatment of nausea and vomiting in terminally ill cancer patients.

Authors:  Paul A Glare; David Dunwoodie; Katherine Clark; Alicia Ward; Patsy Yates; Sharon Ryan; Janet R Hardy
Journal:  Drugs       Date:  2008       Impact factor: 9.546

7.  [Treatment of nausea and vomiting with 5HT3 receptor antagonists, steroids, antihistamines, anticholinergics, somatostatinantagonists, benzodiazepines and cannabinoids in palliative care patients : a systematic review].

Authors:  G Benze; A Geyer; B Alt-Epping; F Nauck
Journal:  Schmerz       Date:  2012-09       Impact factor: 1.107

8.  Undertreatment of nausea and other symptoms in hospitalized cancer patients.

Authors:  Judi Greaves; Paul Glare; Linda J Kristjanson; Martin Stockler; Martin H N Tattersall
Journal:  Support Care Cancer       Date:  2008-10-18       Impact factor: 3.603

9.  Sublingually administered scopolamine for nausea in terminally ill cancer patients.

Authors:  Kengo Imai; Masayuki Ikenaga; Tomoyuki Kodama; Seitetsu Kanemura; Keiko Tamura; Tatsuya Morita
Journal:  Support Care Cancer       Date:  2013-05-31       Impact factor: 3.603

Review 10.  Treating nausea and vomiting in palliative care: a review.

Authors:  Paul Glare; Jeanna Miller; Tanya Nikolova; Roma Tickoo
Journal:  Clin Interv Aging       Date:  2011-09-12       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.